

R&D Pipeline

(As of December 3, 2024)



Code Generic name (Product name)	Indication	Preclinical	Clinical Trial	Application Approval	Mechanism
JR-141 pabinafusp alfa (IZCARGO® for I.V. infusion 10mg)	MPS type II (Hunter)		Global Ph3		BBB-penetrating iduronate-2-sulfatase (rDNA origin)
JR-171 lepunafusp alfa	MPS type I(Hurler etc.)		Global Ph1/2		BBB-penetrating α-L-iduronidase (rDNA origin)
JR-142	Pediatric growth hormone deficiency		Japan Ph2		Long-acting human growth hormone (rDNA origin)
JR-441	MPS type III A (Sanfilippo A)		Global Ph1/2		BBB-penetrating heparan N-sulfatase (rDNA origin)
JR-446	MPS type III B (Sanfilippo B)		Japan Ph1/2		BBB-penetrating α-N-acetylglucosam (rDNA origin)
JR-471	Fucosidosis				BBB-penetrating α-L-fucosidase (rDNA origin)

※Only high-priority projects in the clinical stage or soon to be in the clinical stage are listed in the above table.